Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company that focuses on developing medicines that treat intractable diseases by silencing the genes that cause them. The company is part of a competitive industry with peers like Alnylam Pharmaceuticals, ACADIA Pharmaceuticals, and Axsome Therapeutics. These companies are all engaged in the development of innovative therapies, making the efficient use of capital crucial for success.
Arrowhead Pharmaceuticals has a Return on Invested Capital (ROIC) of 20.84%, which is significantly higher than its Weighted Average Cost of Capital (WACC) of 9.83%. This results in a ROIC to WACC ratio of 2.12, indicating that the company is effectively utilizing its capital to generate returns that exceed its cost of capital. This is a positive sign for investors, as it suggests that Arrowhead is creating value through its investments.
In comparison, Alnylam Pharmaceuticals has a ROIC of 13.74% and a WACC of 5.68%, resulting in a ROIC to WACC ratio of 2.42. While Alnylam's ratio is higher than Arrowhead's, both companies demonstrate efficient capital utilization.
ACADIA Pharmaceuticals stands out with a ROIC of 23.32% and a WACC of 6.72%, resulting in the highest ROIC to WACC ratio among the peers at 3.47. This suggests that ACADIA is the most efficient in utilizing its capital relative to its cost, indicating strong potential for growth and value creation. Meanwhile, Axsome Therapeutics has a negative ROIC of -43.39% and a WACC of 5.50%, resulting in a ROIC to WACC ratio of -7.89, highlighting inefficiencies in capital utilization.
